The Non-invasive prenatal test for common recessive conditions and aneuploidies
Plus optional Red blood cell fetal Antigens
Maternal carrier screen2 is performed before single-gene NIPT
* fetal sex optional, available for twins
C, c, E, D,Duffy (Fya), and Kell (K)
(applicable for alloimmunized patients)
1: For general population screening, excluding population-specific recommendations (e.g., Ashkenazi Jewish populations) and individual family history. While ACOG recommends testing of such genetic conditions, not all modalities of screen specifically require sgNIPT.
2: Screening for fragile X syndrome (FXS), an X-linked condition, is also available. UNITY screens maternal blood to determine the number of CGG repeats she has in her FMR1 gene.
Did You Know
58.5%
of carrier-positive mothers do not follow up with paternal testing
Know early to explore treatments.
There are emerging therapies for conditions previously considered to be untreatable that you may not know about. Identifying high-risk pregnancies early may open the door to new treatments, significantly impacting baby’s health.
Add fetal antigens to order if applicable.
Collect three tubes of maternal blood.
Ship the sample using pre-labeled kit.
Complimentary genetic counseling sessions are available to all patients, before or after taking the test.
All insurances including Medicaid are accepted and financial assistance is available.
We are here for you.
Complimentary genetic counseling is available before or after taking the test. Our board-certified genetic counselors are here to guide you through the process.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Streamline management of alloimmunized patients with non-invasive screening for fetal antigens
While rare, Hemolytic Disease of the Fetus and Newborn (HDFN) can be deadly. Screening for C, c, D, E, Duffy (Fya), and Kell (K) antigens can now be added to any UNITY aneuploidy order.
If patient is alloimmunized for C, c, D, E, Duffy (Fya), or Kell (K):
2. ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy. Obstet Gynecol. 2018 Mar;131(3):e82-e90. doi: 10.1097/AOG.0000000000002528. PMID: 29470342.48(5):941-52. doi: 10.1111/j.1537- 2995.2007.01625.x. Epub 2008 Feb 1. PMID: 18248570. 3. Koelewijn JM, et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion. 2008 May; 48(5):941-52. doi: 10.1111/j.1537-2995.2007.01625.x. Epub 2008 Feb 1. PMID: 18248570.
NEW! For alloimmunized patients, UNITY now screens for the presence of red blood cell fetal antigens non-invasively and early in pregnancy
UNITY™ sgNIPT has shown > 98.5% sensitivity and >99% specificity in a peer reviewed publication.
It has also shown 100% concordance with newborn screen results in NIH-sponsored clinical study with Baylor College of Medicine and a study with University of Alabama Birmingham.
Single-Molecule Accuracy Powered by QCT™
Using QCT™ molecular counting technology, UNITY™ is able to differentiate homozygous affected fetus (colored bars) from carrier fetus (gray bar). In addition, UNITY™ performs a paternal allele assay to detect a fetus at-risk to be compound heterozygous for CFTR or HBB at >98% detection rate.
Exemplary Readout. Chromosome 21 Ratio: euploid vs trisomy 21
UNITY™ sgNIPT and Aneuploidy + RhD NIPT use synthetic molecules and computational decoding in the bioinformatics stage to reduce the assay amplification noise down to the theoretical limit. Thanks to these proprietary technologies, UNITY™ can uniquely offer reflex sgNIPT and Rh NIPT solutions.
NEW! For alloimmunized patients, UNITY now screens for the presence of RBC fetal antigens associated with severe HDFN
While rare, Hemolytic Disease of the Fetus and Newborn (HDFN) can be deadly. Screening for C, c, D, E, Duffy (Fya), and Kell (K) antigens can now be added to any UNITY aneuploidy order.